Wyeth received marketing authorization from the European Commission for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. “Analyses of clinical trial data showed that treatment with Conbriza significantly decreased the risk of all clinical fractures and non-vertebral fractures for women who were at a greater risk of osteoporotic fracture,” says Gary L. Stiles, M.D., exec...